-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Aprea Therapeutics, Lowers Price Target to $1.2

Benzinga·03/31/2026 11:16:24
Listen to the news
HC Wainwright & Co. analyst Joseph Pantginis maintains Aprea Therapeutics (NASDAQ:APRE) with a Buy and lowers the price target from $4 to $1.2.